UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Lung cancer (Amsterdam, Netherlands), 2015-12, Vol.90 (3), p.509-515

2015

Volltextzugriff (PDF)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Journal of thoracic oncology, 2014-09, Vol.9 (9), p.1345-1353

2014

Volltextzugriff (PDF)

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial

Gynecologic oncology, 2021-12, Vol.163 (3), p.563-568

2021

Volltextzugriff (PDF)

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

Journal of thoracic oncology, 2017-08, Vol.12 (8), p.1247-1256

2017

Volltextzugriff (PDF)

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)

American journal of cancer research, 2015-01, Vol.5 (9), p.2892-2911

2015

Volltextzugriff (PDF)

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Journal of clinical pathology, 2013-02, Vol.66 (2), p.79-89

2013

Volltextzugriff (PDF)

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2019-11, Vol.25 (22), p.6644-6652

2019

Volltextzugriff (PDF)

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

Journal of experimental & clinical cancer research, 2015-09, Vol.34 (1), p.92-92, Article 92

2015

Volltextzugriff (PDF)

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Clinical cancer research, 2023-01, Vol.29 (1), p.81-91

2023

Volltextzugriff (PDF)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Clinical cancer research, 2023-01, Vol.29 (1), p.92-99

2023

Volltextzugriff (PDF)

Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9137-TPS9137

2022

Volltextzugriff (PDF)

Concordance of BRCA1 , BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.26-26

2021

Volltextzugriff (PDF)

Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy

Scientific reports, 2019-08, Vol.9 (1), p.11992-17, Article 11992

2019

Volltextzugriff (PDF)

The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20000 ovarian tumors identified using next‐generation sequencing

Genes chromosomes & cancer, 2023-10, Vol.62 (10), p.589-596

2023

Volltextzugriff (PDF)

EGFR T790M mutation testing within the osimertinib AURA Phase I study

Lung cancer (Amsterdam, Netherlands), 2017-07, Vol.109, p.9-13

2017

Volltextzugriff (PDF)

The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing

Genes chromosomes & cancer, 2023-10, Vol.62 (10), p.589-596

2023

Volltextzugriff (PDF)

EGFR T790M mutation testing within a phase I study with AZD9291

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e19051-e19051

2014

Volltextzugriff (PDF)

Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1 , BRCA2 or ATM : Results from the PROfound study

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.27-27

2021

Volltextzugriff (PDF)

EN2-2. DESTINY-Lung04 : Trastuzumab deruxtecan as 1L treatment in advanced HER2 exon 19 or 20 mutated NSCLC

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.560-560

2022

Volltextzugriff (PDF)

Analysis of tumor samples from SOLO2: Concordance of BRCA mutation ( BRCA m) detection in tumor vs. blood and frequency of BRCA -specific loss of heterozygosity (LOH) and loss of function somatic mutations

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12017-12017

2018

Volltextzugriff (PDF)

Abstract A8: Mutation mapping in non-small cell lung cancer: A meta-analysis by geography and histology (MutMap)

Clinical cancer research, 2012-02, Vol.18 (3_Supplement), p.A8-A8

2012

Volltextzugriff (PDF)

Identification of a Subset of Human Non-Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Clinical cancer research, 2014-02, Vol.20 (3), p.595-603

2014

Volltextzugriff (PDF)

Pseudoautosomal linkage of familial hodgkin's lymphoma: molecular analysis of a unique family with leri–weill dyschondrosteosis and hodgkins lymphoma

British journal of haematology, 2003-04, Vol.121 (2), p.377-379

2003

Volltextzugriff (PDF)

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib

European journal of cancer (1990), 2013-07, Vol.49 (10), p.2424-2432

2013

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(75)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(33)
Humans
(25)
Oncology
(18)
Female
(12)
Mutation
(11)
Male
(10)
Carcinoma, Non-Small-Cell Lung - Genetics
(7)
Lung Neoplasms - Genetics
(7)
Medical Sciences
(7)
Physical Sciences
(7)
Antineoplastic Agents - Therapeutic Use
(6)
Biological And Medical Sciences
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Lung Neoplasms - Drug Therapy
(6)
Medicine
(6)
Medicine & Public Health
(6)
Middle Aged
(6)
Dna Mutational Analysis
(5)
Erbb Receptors - Genetics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04)

Concordance of BRCA1 , BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study

Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy

The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20000 ovarian tumors identified using next‐generation sequencing

EGFR T790M mutation testing within the osimertinib AURA Phase I study

The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing

EGFR T790M mutation testing within a phase I study with AZD9291

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1 , BRCA2 or ATM : Results from the PROfound study

EN2-2. DESTINY-Lung04 : Trastuzumab deruxtecan as 1L treatment in advanced HER2 exon 19 or 20 mutated NSCLC

Analysis of tumor samples from SOLO2: Concordance of BRCA mutation ( BRCA m) detection in tumor vs. blood and frequency of BRCA -specific loss of heterozygosity (LOH) and loss of function somatic mutations

Abstract A8: Mutation mapping in non-small cell lung cancer: A meta-analysis by geography and histology (MutMap)

Identification of a Subset of Human Non-Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Pseudoautosomal linkage of familial hodgkin's lymphoma: molecular analysis of a unique family with leri–weill dyschondrosteosis and hodgkins lymphoma

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib

Suchergebnisse filtern